Page 64 - TI Journal 18-1
P. 64

58                                      COHEN



          Rokka, J.; Karrasch, M.; Parkkola, R.; Rinne, J.   31.  Levine, H., 3 . Thioflavin T interaction with
                                                                  rd
          O. Five-year follow-up of 11C-PIB uptake in   amyloid b-sheet structures. Amyloi. 2:1-6; 1995.
          Alzheimer’s disease and MCI. Eur. J. Nucl. Med.   32.  Lopresti, B. J.; Klunk, W. E.; Mathis, C. A.;
          Mol. Imaging 41(2):283-289; 2014.            Hoge, J. A.; Ziolko, S. K.; Lu, X.; Meltzer, C. C.;
      26.  Klunk, W. E.; Engler, H.; Nordberg, A.; Wang,   Schimmel, K.; Tsopelas, N. D.; DeKosky, S. T.;
          Y.; Blomqvist, G.; Holt, D. P.; Bergstrom, M.;   Price, J.C. Simplified quantification of Pittsburgh
          Savitcheva, I.; Huang, G. F.; Estrada, S.; Ausén,   Compound B amyloid imaging PET studies: a
          B.; Debnath, M.L.; Barletta, J.; Price, J.C.; Sandell,   comparative analysis. J. Nucl. Med. 46(12):1959-
          J.; Lopresti, B.J.; Wall, A.; Koivisto, P.; Antoni,   1972; 2005.
          G.; Mathis, C.A.; Långström, B. Imaging brain   33.  Mathis, C. A.; Wang, Y.; Holt, D. P.; Huang, G.
          amyloid in Alzheimer’s disease with Pittsburgh   F.; Debnath, M. L.; Klunk, W. E. Synthesis and
          Compound-B. Ann. Neurol. 55(3):306-319; 2004.  evaluation of 11C-labeled 6-substituted 2-aryl-
      27.  Klunk, W. E.; Lopresti, B. J.; Ikonomovic, M. D.;   benzothiazoles as amyloid imaging agents. J. Med.
          Lefterov, I. M.; Koldamova, R. P.; Abrahamson, E.   Chem. 46(13):2740-2754; 2003.
          E.; Debnath, M. L.; Holt, D. P.; Huang, G. F.; Shao,   34.  Mintun, M. A.; Larossa, G. N.; Sheline, Y. I.;
          L.; deKosky, S.T.; Price, J.C.; Mathis, C.A. Binding   Dence, C. S.; Lee, S. Y.; Mach, R. H.; Klunk, W.
          of the positron emission tomography tracer   E.; Mathis, C. A.; DeKosky, S. T.; Morris, J. C.
          Pittsburgh compound-B reflects the amount    [11C]PIB in a nondemented population: poten-
          of amyloid-beta in Alzheimer’s disease brain   tial antecedent marker of Alzheimer disease.
          but not in transgenic mouse brain. J. Neurosci.   Neurology 67(3):446-452; 2006.
          25(46):10598-10606; 2005.                 35.  Mormino, E. C.; Kluth, J. T.; Madison, C. M.;
      28.  Koivunen, J.; Scheinin, N.; Virta, J. R.; Aalto, S.;   Rabinovici, G. D.; Baker, S. L.; Miller, B. L.;
          Vahlberg, T.; Nagren, K.; Helin, S.; Parkkola, R.;   Koeppe, R. A.; Mathis, C. A.; Weiner, M. W.;
          Viitanen, M.; Rinne, J. O. Amyloid PET imaging   Jagust, W. J. Episodic memory loss is related to
          in patients with mild cognitive impairment: a   hippocampal-mediated beta-amyloid deposition
          2-year follow-up study. Neurology 76(12):1085-  in elderly subjects. Brain 132(Pt 5):1310-1323;
          1090; 2011.                                  2009.
      29.  Landt, J.; D’Abrera, J. C.; Holland, A. J.; Aigbirhio,   36.  Mormino, E. C.; Smiljic, A.; Hayenga, A. O.; S, H.
          F. I.; Fryer, T. D.; Canales, R.; Hong, Y. T.; Menon,   O.; Greicius, M. D.; Rabinovici, G. D.; Janabi, M.;
          D. K.; Baron, J. C.; Zaman, S. H. Using positron   Baker, S. L.; I, V. Y.; Madison, C. M.; Miller, B.L.;
          emission tomography and Carbon 11-labeled    Jagust, W.J. Relationships between β-amyloid and
          Pittsburgh Compound B to image Brain Fibrillar   functional connectivity in different components
          beta-amyloid in adults with down syndrome:    of the default mode network in aging. Cereb.
          safety, acceptability, and feasibility. Arch. Neurol.   Cortex 21(10):2399-2407; 2011.
          68(7):890-896; 2011.                      37.  Morris, J. C.; Roe, C. M.; Xiong, C.; Fagan, A.
      30.  Lao, P. J.; Betthauser, T. J.; Hillmer, A. T.; Price,   M.; Goate, A. M.; Holtzman, D. M.; Mintun,
          J. C.; Klunk, W. E.; Mihaila, I.; Higgins, A.   M. A. APOE predicts amyloid-beta but not tau
          T.; Bulova, P. D.; Hartley, S. L.; Hardison, R.;   Alzheimer pathology in cognitively normal aging.
          Tumuluru, R.V.; Murali, D.; Mathis, C.A.; Cohen,   Ann. Neurol. 67(1):122-131; 2010.
          A.D.; Barnhart, T.E.; Devenny, D.A.; Mailick,   38.  Nebes, R. D.; Snitz, B. E.; Cohen, A. D.; Aizenstein,
          M.R.; Johnson, S.C.; Handen, B.L.; Christian,   H. J.; Saxton, J. A.; Halligan, E. M.; Mathis, C.
          B.T. The effects of normal aging on amyloid-beta   A.; Price, J. C.; Kamboh, M. I.; Weissfeld, L. A.;
          deposition in nondemented adults with Down   Klunk, W.E. Cognitive aging in persons with
          syndrome as imaged by carbon 11-labeled       minimal amyloid-beta and white matter hyper-
          Pittsburgh compound B. Alzheimers Dement.     intensities. Neuropsychologia 51(11):2202-2209;
          1-11; 2015.                                  2013.
   59   60   61   62   63   64   65   66   67   68   69